Zydus Lifesciences’ subsidiary, Amplitude Surgical, has secured CE mark approval for its robotic surgical system, ‘Andy’. This milestone confirms compliance with European safety, performance, and quality standards. Andy is built with Amplitude’s proprietary navigation platform, Amplivision, and integrates robotic assistance through collaboration with eCential Robotics. This approval expands the EU market opportunity and marks advancement in orthopaedic surgery.
‘Andy’ Receives CE Mark
Amplitude Surgical, a subsidiary of Zydus Lifesciences, announced on November 13, 2025, that its robotic surgical system, ‘Andy’, has received CE mark approval. This confirms compliance with European standards for safety, performance, and quality. The system aims to enhance orthopaedic surgical procedures.
Technology and Innovation
‘Andy’ integrates Amplitude’s Amplivision navigation technology with robotic assistance, developed through a strategic collaboration with eCential Robotics. The robotic surgical system is conceived as a true surgical partner, using proprietary technology capable of performing bone resections with precision and reliability.
Enhanced Surgical Capabilities
The ‘Andy’ robotic surgical system delivers enhanced accuracy and consistency. It enables optimal alignment while minimizing tissue trauma, which intends to result in smaller incisions, reduced pain, faster recovery, and fewer complications, ultimately enhancing knee function, shortening hospital stays, and ensuring long-term implant performance.
Strategic Acquisition
Earlier in 2025, Zydus MedTech expanded its global presence with the strategic acquisition of Amplitude Surgical. Amplitude Surgical is a European MedTech company specializing in high-quality lower-limb orthopaedic technologies. This acquisition strengthens Zydus MedTech’s commitment to delivering advanced, patient-focused solutions through cutting-edge research, design innovation, and precision engineering.
Source: BSE
